Clinical studies in lysosomal storage diseases

References

• Pastores GM. Therapeutic approaches for lysosomal storage diseases. Ther Adv Endocrinol Metab 2010; 1:177 - 88; http://dx.doi.org/10.1177/2042018810384429; PMID: 23148162
   PubMedGoogle Scholar
• Haffner ME. Adopting orphan drugs--two dozen years of testing rare diseases. N Engl J Med 2006; 345:4457
   Google Scholar
• Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N’Diamoi C, et al, Committee for Orphan Medicinal Products and the European Medicines. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011; 10:341 - 9; http://dx.doi.org/10.1038/nrd3445; PMID: 21532564
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011; 305:2320 - 6; http://dx.doi.org/10.1001/jama.2011.769; PMID: 21642684
   PubMed Web of Science ®Google Scholar
• Coté TR, Xu K, Pariser AR. Accelerating orphan drug development. Nat Rev Drug Discov 2010; 9:901 - 2; http://dx.doi.org/10.1038/nrd3340; PMID: 21119719
   PubMed Web of Science ®Google Scholar
• Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11:191 - 200; http://dx.doi.org/10.1038/nrd3681; PMID: 22378269
   PubMed Web of Science ®Google Scholar
• Gottlieb S. Changing the FDA’s culture. National Affairs 2012; 12:108 - 21
   Google Scholar
• Sasinovski FJ. Quantum of effectiveness evidence in FDA’s approval of Orphan Drugs [Internet]. Washington (DC): National Organization for Rare Disorders: c2011 [cited 2013 Aug 24]. Available from: http://www.rarediseases.org/docs/policy/NORDstudyofFDAapprovaloforphandrugs.pdf
   Google Scholar
• Shire Provides Update on US Biologics License Application Filing for REPLAGAL® (agalsidase alfa) [Internet]. Dublin, Ireland; Shire; c2012 March 12 [cited 2013 August 24]. Available from: http://www.shire.com/shireplc/en/investors/irshirenews?id=577
   Google Scholar
• Crowley J. Statement of John Crowley, Chief Executive Officer and Chairman of Amicus Therapeutics on behalf of the biotechnology industry organization [Internet]. Washington (DC); US Senate Committee on Health, Education, Labor and Pensions; c2010 July 21 [cited 2013 August 24]. Available from: www.help.senate.gov/imo/media/doc/Crowley.pdf
   Google Scholar
• Johnson JR, Ning Y-M, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 2011; 103:636 - 44; http://dx.doi.org/10.1093/jnci/djr062; PMID: 21422403
   PubMed Web of Science ®Google Scholar
• Anonymous. Reforming accelerated approval. Nat Biotechnol 2012; 30:293; http://dx.doi.org/10.1038/nbt.2194; PMID: 22491259
   PubMed Web of Science ®Google Scholar
• European public assessment reports. Conditional approval. Authorized medecines [Internet]. European Medicines Agency; c2013 [cited 2013 August 24]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d125&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=ca&genericsKeywordSearch=Submit
   Google Scholar
• Boon WPC, Moors EHM, Meijer A, Schellekens H. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther 2010; 88:848 - 53; http://dx.doi.org/10.1038/clpt.2010.207; PMID: 20962774
   PubMed Web of Science ®Google Scholar
• Molzon JA, Giaquinto A, Lindstrom L, Tominaga T, Ward M, Doerr P, Hunt L, Rago L. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health. Clin Pharmacol Ther 2011; 89:503 - 12; http://dx.doi.org/10.1038/clpt.2011.10; PMID: 21326288
   PubMed Web of Science ®Google Scholar
• Emanuel EJ, Miller FG. The ethics of placebo-controlled trials--a middle ground. N Engl J Med 2001; 345:915 - 9; http://dx.doi.org/10.1056/NEJM200109203451211; PMID: 11565527
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Germain DP, Hollak CEM, Hughes D, Rolfs A, Wanner C, Mehta A, European Medicines Agency. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011; 102:99 - 102; http://dx.doi.org/10.1016/j.ymgme.2010.11.155; PMID: 21123099
   PubMed Web of Science ®Google Scholar
• Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA, Rare Diseases Clinical Research Network. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96:20 - 6; http://dx.doi.org/10.1016/j.ymgme.2008.10.003; PMID: 19013090
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 1991; 324:1464 - 70; http://dx.doi.org/10.1056/NEJM199105233242104; PMID: 2023606
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122:33 - 9; http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00005; PMID: 7985893
   PubMed Web of Science ®Google Scholar
• Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144:581 - 8; http://dx.doi.org/10.1016/j.jpeds.2004.01.046; PMID: 15126990
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. [published correction appears in Neurology 2008; 71:1748] Neurology 2007; 68:99 - 109; http://dx.doi.org/10.1212/01.wnl.0000251268.41188.04; PMID: 17151339
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human α-galactosidase A--replacement therapy in Fabry’s disease. N Engl J Med 2001; 345:9 - 16; http://dx.doi.org/10.1056/NEJM200107053450102; PMID: 11439963
   PubMed Web of Science ®Google Scholar
• Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, et al, Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77 - 86; http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00148; PMID: 17179052
   PubMed Web of Science ®Google Scholar
• van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010; 362:1396 - 406; http://dx.doi.org/10.1056/NEJMoa0909859; PMID: 20393176
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311:485; http://dx.doi.org/10.1136/bmj.311.7003.485; PMID: 7647644
   PubMed Web of Science ®Google Scholar
• Temple RJ. Special study designs: early escape, enrichment, studies in non-responders. Comm Statist Theory Methods 1994; 23:499 - 531; http://dx.doi.org/10.1080/03610929408831269
   Web of Science ®Google Scholar
• Temple R. Enrichment of clinical study populations. Clin Pharmacol Ther 2010; 88:774 - 8; http://dx.doi.org/10.1038/clpt.2010.233; PMID: 20944560
   PubMed Web of Science ®Google Scholar
• Kalydeco™ package insert [Internet]. Washington (DC); Vertex Pharmaceuticals Inc.; c2012 [cited 2013 August 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203188lbl.pdf
   Google Scholar
• Study of the effects of oral AT1001 (Migalastat hydrochloride) in Patients with Fabry Disease [Internet]. Washington (DC); Clinicaltrials.gov.; c2013 [cited 2013 August 24]. Available from: http://clinicaltrials.gov/ct2/results?term=migalastat
   Google Scholar
• Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP, Schiffmann R, Boudes P, Lockhart DJ, Valenzano KJ, et al. A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat 2011; 32:965 - 77; http://dx.doi.org/10.1002/humu.21530; PMID: 21598360
   PubMed Web of Science ®Google Scholar
• Emanuel EJ, Miller FG. The ethics of placebo-controlled trials--a middle ground. N Engl J Med 2001; 345:915 - 9; http://dx.doi.org/10.1056/NEJM200109203451211; PMID: 11565527
   PubMed Web of Science ®Google Scholar
• Lagakos SW. Clinical trials and rare diseases. N Engl J Med 2003; 348:2455 - 6; http://dx.doi.org/10.1056/NEJMe030024; PMID: 12802033
   PubMed Web of Science ®Google Scholar
• Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 1996; 125:605 - 13; http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00011; PMID: 8815760
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979; 90:85 - 91; http://dx.doi.org/10.7326/0003-4819-90-1-85; PMID: 217290
   PubMed Web of Science ®Google Scholar
• Clarke LA, Winchester B, Giugliani R, Tylki-Szymańska A, Amartino H. Biomarkers for the mucopolysaccharidoses: discovery and clinical utility. Mol Genet Metab 2012; 106:395 - 402; http://dx.doi.org/10.1016/j.ymgme.2012.05.003; PMID: 22658917
   PubMed Web of Science ®Google Scholar
• Young SP, Zhang H, Corzo D, Thurberg BL, Bali D, Kishnani PS, Millington DS. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med 2009; 11:536 - 41; http://dx.doi.org/10.1097/GIM.0b013e3181a87867; PMID: 19521244
   PubMed Web of Science ®Google Scholar
• Hollak CEM, van Weely S, van Oers MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93:1288 - 92; http://dx.doi.org/10.1172/JCI117084; PMID: 8132768
   PubMed Web of Science ®Google Scholar
• Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004; 65:299 - 307; http://dx.doi.org/10.1111/j.1399-0004.2004.00219.x; PMID: 15025723
   PubMed Web of Science ®Google Scholar
• Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, et al. A validated disease severity scoring system for Fabry disease. Mol Genet Metab 2010; 99:283 - 90; http://dx.doi.org/10.1016/j.ymgme.2009.10.178; PMID: 19951842
   PubMed Web of Science ®Google Scholar
• Hughes DA, Malmenäs M, Deegan PB, Elliott PM, Ginsberg L, Hajioff D, Ioannidis AS, Orteu CH, Ramaswami U, West M, et al, FOS Investigators. Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. J Med Genet 2012; 49:212 - 20; http://dx.doi.org/10.1136/jmedgenet-2011-100407; PMID: 22315436
   PubMed Web of Science ®Google Scholar
• Chow S-C, Corey R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis 2011; 6:79 - 89; http://dx.doi.org/10.1186/1750-1172-6-79; PMID: 22129361
   PubMed Web of Science ®Google Scholar
• Chow SC, Chang M, Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat 2005; 15:575 - 91; http://dx.doi.org/10.1081/BIP-200062277; PMID: 16022164
   PubMed Web of Science ®Google Scholar
• Gallo P, Anderson K, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J Biopharm Stat 2010; 20:1115 - 24; http://dx.doi.org/10.1080/10543406.2010.514452; PMID: 21058107
   PubMed Web of Science ®Google Scholar
• FDA Draft Guidance for Industry - Adaptive Design Clinical Trials for Drugs and Biologics. The United State Food and Drug Administration, Rockville, Maryland. 2010.
   Google Scholar
• Yao L. Clinical background materials. Alglucosidase alfa 2000 L product for the treatment of Late-Onset Pompe Disease [Internet]. Washington (DC); FDA CDER. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting; c2008 Oct 21 [cited 2013 August 24]. Available from: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4389b1-01-FDA.pdf
   Google Scholar
• European Medicinal Agency (EMA). Point to Consider on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. CPMP/EWP/2459/02, London, UK 2002.
   Google Scholar
• European Medicinal Agency (EMA). Reflection paper on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. CPMP/EWP/2459/02, London, UK 2006.
   Google Scholar
• Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002; 113:112 - 9; http://dx.doi.org/10.1016/S0002-9343(02)01150-6; PMID: 12133749
   PubMed Web of Science ®Google Scholar
• Byrne BJ, Kishnani PS, Case LE, Merlini L, Müller-Felber W, Prasad S, van der Ploeg A. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 2011; 103:1 - 11; http://dx.doi.org/10.1016/j.ymgme.2011.02.004; PMID: 21439876
   PubMed Web of Science ®Google Scholar
• Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT, Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 2009; 374:1986 - 96; http://dx.doi.org/10.1016/S0140-6736(09)61493-8; PMID: 19959221
   PubMed Web of Science ®Google Scholar
• Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Leão Teles E, Valayannopoulos V, CSP Study Group. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 2013; 36:373 - 84; http://dx.doi.org/10.1007/s10545-011-9410-9; PMID: 22127392
   PubMed Web of Science ®Google Scholar
• Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43:347 - 52; http://dx.doi.org/10.1136/jmg.2005.036327; PMID: 16227523
   PubMed Web of Science ®Google Scholar
• Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009; 46:548 - 52; http://dx.doi.org/10.1136/jmg.2008.065904; PMID: 19473999
   PubMed Web of Science ®Google Scholar
• Jones S, James E, Prasad S. Disease registries and outcomes research in children: focus on lysosomal storage disorders. Paediatr Drugs 2011; 13:33 - 47; http://dx.doi.org/10.2165/11586860-000000000-00000; PMID: 21162599
   PubMed Web of Science ®Google Scholar
• Hollak CEM, Aerts JMFG, Aymé S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 2011; 6:16; http://dx.doi.org/10.1186/1750-1172-6-16; PMID: 21496291
   PubMed Web of Science ®Google Scholar
• Nicholls K, Germain DP, Feliciani C, et al. Phase 3 Study of Migalastat HCl for Fabry Disease: Stage 1 Results. February 15, 2013, 9th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD)
   Google Scholar
• National conference on alternative IRB models: optimizing subject protection, November 19-21, 2006 [Internet]. Washington (DC): Associations of American Medical Colleges; c2006 [cited 2013 August 24]. Available from: http://www.aamc.org/research/irbreview/irbconf06rpt.pdf
   Google Scholar
• Menikoff J. The paradoxical problem with multiple-IRB review. N Engl J Med 2010; 363:1591 - 3; http://dx.doi.org/10.1056/NEJMp1005101; PMID: 20942660
   PubMed Web of Science ®Google Scholar
• Frequently asked questions: breakthrough therapies [Internet]. Washington (DC): US Food and Drug Administration; c2013 [cited 2013 Aug 24]. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm341027.htm. Accessed 4/16/2013.
   Google Scholar
• Anonymous. Reforming accelerated approval. Nat Biotechnol 2012; 30:293; http://dx.doi.org/10.1038/nbt.2194; PMID: 22491259
   PubMed Web of Science ®Google Scholar
• Cressey D. Europe sets out to reform its clinical trial rules. Nat Rev Drug Discov 2012; 11:660 - 1; http://dx.doi.org/10.1038/nrd3843; PMID: 22935791
   PubMed Web of Science ®Google Scholar
• Numerof RE, Abrams MN. The growing orphan-drug paradigm. Pharmaceutical Tech 2012; May:105 - 6
   Google Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011; 6:42 - 50; http://dx.doi.org/10.1186/1750-1172-6-42; PMID: 21682893
   PubMed Web of Science ®Google Scholar
• McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol 2010; 686:211 - 22; http://dx.doi.org/10.1007/978-90-481-9485-8_13; PMID: 20824448
   PubMed Web of Science ®Google Scholar